Article Text

other Versions

Management, prevention and treatment of canine leishmaniosis in north-eastern Spain: an online questionnaire-based survey in the province of Girona with special emphasis on new preventive methods (CaniLeish vaccine and domperidone)
  1. S. Lladró, DVM, MSc1,
  2. A. Picado, DVM, PhD2,
  3. C. Ballart, BSc, MSc, PhD1,
  4. M. Portús, PharmD, PhD1 and
  5. M. Gállego, PharmD, PhD1
  1. 1Section of Parasitology, Department of Biology, Healthcare and the Environment, Faculty of Pharmacy, Universitat de Barcelona, Avda. Joan XXIII 27-31, 08028 Barcelona, Spain
  2. 2ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic – Universitat de Barcelona, Barcelona, Spain
  3. S. Lladró, C. Ballart, M. Gállego, are also at ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic – Universitat de Barcelona, Barcelona, Spain
  1. Email for correspondence: mgallego{at}


Knowledge of how canine leishmaniosis (CanL) is being managed clinically and its epidemiology is very important, since dogs are the main reservoir of human leishmaniosis. This study reports the results obtained through a questionnaire-based survey of veterinary practitioners in Girona province, a recognised, but non-documented endemic area in north-eastern Spain. The primary objective was to obtain data on the clinical management of CanL, focusing particularly on new preventive methods and therapeutic tools. The results show an extensive routine management of CanL cases and a widespread use of the CaniLeish (Virbac) vaccine and domperidone (Leisguard, Esteve). Adverse reactions were detected by a vast majority of the vaccine users (82 per cent), the most frequent being local reactions, apathy, fever and gastroenteritis. All the respondents had treated confirmed cases, and the therapeutic protocol most used was the combination of meglumine antimoniate (Glucantime, Merial) and allopurinol (Zyloric, GlaxoSmithKline).

  • canine leishmaniasis
  • vaccine
  • prevention
  • web-questionnaire
  • NE Spain

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.